Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 235INDUSTRY 148NIH 48NETWORK 6OTHER_GOV 2UNKNOWN 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cisplatin 50Capecitabine 42apatinib 34Radiotherapy 33Oxaliplatin 33Gemcitabine 33Cyclophosphamide 32Drug Therapy 31Paclitaxel 30Carboplatin 29tislelizumab 27Irinotecan 27Fluorouracil 26Docetaxel 26Bevacizumab 23Surgical Procedures, Operative 21Nivolumab 19pembrolizumab 18fludarabine 18Radiation 16Metformin 16Exercise 16camrelizumab 15S 1 (combination) 14Control Groups 14Blood Specimen Collection 14Pemetrexed 13Standard of Care 12anlotinib 11Neoadjuvant Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Sunitinib × Clear all
NCT02626754 2018-06-26

A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population

Taipei Veterans General Hospital, Taiwan

Phase 2 Terminated
13 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00620347 2013-06-19

Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer

National Cancer Center, Korea

Phase 2 Completed
25 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡